Outlook Therapeutics, Inc. financial data

Symbol
OTLK on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
111 S. Wood Avenue, Unit #100, Iselin, New Jersey
State of incorporation
Delaware
Fiscal year end
September 30
Former names
Oncobiologics, Inc. (to 11/13/2018)
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 77.4 % -58.4%
Debt-to-equity -188 % -180%
Return On Equity 357 %
Return On Assets -404 % -225%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23.4 M shares -90.9%
Common Stock, Shares, Outstanding 22 M shares -91.4%
Entity Public Float 180 M USD -19%
Common Stock, Value, Issued 220 K USD -91.4%
Weighted Average Number of Shares Outstanding, Basic 14.3 M shares +11.2%
Weighted Average Number of Shares Outstanding, Diluted 14.3 M shares +11.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 34.1 M USD +11.2%
General and Administrative Expense 25.8 M USD +12.6%
Operating Income (Loss) -59.9 M USD -11.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -114 M USD -1618%
Income Tax Expense (Benefit) 2.8 K USD 0%
Net Income (Loss) Attributable to Parent -159 M USD -178%
Earnings Per Share, Basic -7.69 USD/shares -939%
Earnings Per Share, Diluted -7.69 USD/shares -939%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 47.2 M USD +8.25%
Assets, Current 57.8 M USD +8.92%
Property, Plant and Equipment, Net 40.9 K USD -80%
Operating Lease, Right-of-Use Asset 3.74 K USD -92.3%
Other Assets, Noncurrent 473 K USD +316%
Assets 59 M USD +9.26%
Accounts Payable, Current 4.36 M USD +20.5%
Employee-related Liabilities, Current 1.14 M USD -31.4%
Accrued Liabilities, Current 3.12 M USD -49.9%
Liabilities, Current 54.1 M USD +24.2%
Operating Lease, Liability, Noncurrent 3.93 K USD
Liabilities 193 M USD +344%
Retained Earnings (Accumulated Deficit) -593 M USD -36.6%
Stockholders' Equity Attributable to Parent -134 M USD -1380%
Liabilities and Equity 59 M USD +9.26%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13 M USD -46.4%
Net Cash Provided by (Used in) Financing Activities 43.8 M USD -34.2%
Common Stock, Shares Authorized 60 M shares -85.9%
Common Stock, Shares, Issued 22 M shares -91.4%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -13 M USD -137%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 47.2 M USD +8.25%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.16 M USD +5650%
Deferred Tax Assets, Valuation Allowance 120 M USD +16.7%
Deferred Tax Assets, Gross 120 M USD +16.6%
Operating Lease, Liability 3.93 K USD -92%
Depreciation 164 K USD +0%
Lessee, Operating Lease, Liability, to be Paid 3.95 K USD -92.3%
Property, Plant and Equipment, Gross 1.07 M USD 0%
Operating Lease, Liability, Current 3.93 K USD -91.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.95 K USD -85.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 25 USD -98.9%
Deferred Tax Assets, Operating Loss Carryforwards 93 M USD +10.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 7.3 M shares 0%
Unrecognized Tax Benefits 1.86 M USD 0%
Operating Lease, Payments 11.9 K USD +2.94%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 7.36 K USD -62.8%
Share-based Payment Arrangement, Expense 5.35 M USD -3%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%